Home | All primary_outcomes

[RDF data]
Primary Outcomes #10496

Resource URI: http://static.linkedct.org/resource/primary_outcomes/10496
rdfs:label Primary Outcomes #10496
linkedct:measure Immune resp. of HER-2/neu by serum antibody titers, delayed hypersensitivity to HER-2/neu-derived peptides, and CD4+ T-cell resp. by ELISPOT at days 28-42 after each vaccination and days 56-84 after third vaccination
is linkedct:primary_outcomes of <http://static.linkedct.org/resource/trials/NCT00093834>
linkedct:primary_outcomes_id 10496 (xsd:int)
linkedct:safety_issue No
rdf:type linkedct:primary_outcomes